Amarin comments on recent innovations for patients with elevated triglycerides

Amarin (AMRN) commented on recent innovations in therapies for patients with elevated triglycerides and shared its perspective on how these developments stand to shape patient access and treatment strategies. Specifically, new therapies for these patients are likely to expand the use of existing, proven options over time, including Amarin’s VASCEPA/VAZKEPA. In addition, through its approved indication for severe hypertriglyceridemia, which is defined as TG greater than or equal to500 mg/dL, as well as strong clinical evidence, affordability, and broad reimbursement, VASCEPA/VAZKEPA aligns with current payor-driven step therapy programs, which require patients to try existing safe and efficacious treatment options before newer, more expensive sHTG alternatives.